Drug intelligence / Profile preview

Parcel

Development stage
Unknown
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral
01

Overview

**Parcel** is an oral fixed-dose analgesic and antimigraine product containing dihydroergotamine mesylate, paracetamol, and caffeine. Dihydroergotamine is an ergot-derived serotonergic agonist that promotes cranial vasoconstrictive antimigraine activity; paracetamol provides analgesia; and caffeine acts as an analgesic adjuvant. Each coated tablet contains dihydroergotamine mesylate 1 mg, paracetamol 450 mg, and caffeine 40 mg. It has been used for symptomatic treatment of headache and migraine and was evaluated in a Phase 3 non-inferiority study in tension-type headache. ([consultaremedios.com.br](https://consultaremedios.com.br/parcel/bula))

Brand names
Parcel
Other names
cafeína + mesilato de diidroergotamina + paracetamoldihydroergotamine mesylate + paracetamol + caffeine
02

Targets

ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Parcel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parcel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call